NabGen Inc.
The startup is developing a platform technology that functions as a universal antibody suppressant to inhibit anti-drug and anti-transplant antibodies, as well as treat autoimmune diseases. This approach specifically targets and blocks AAV-neutralizing antibody activity, enabling effective re-administration of gene therapies using adeno-associated virus vectors despite pre-existing immunity.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$750KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup is developing a platform technology that functions as a universal antibody suppressant to inhibit anti-drug and anti-transplant antibodies, as well as treat autoimmune diseases. This approach specifically targets and blocks AAV-neutralizing antibody activity, enabling effective re-administration of gene therapies using adeno-associated virus vectors despite pre-existing immunity.